323 related articles for article (PubMed ID: 34804076)
21. Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis.
Kubista B; Trieb K; Blahovec H; Kotz R; Micksche M
Anticancer Res; 2002; 22(2A):789-92. PubMed ID: 12014651
[TBL] [Abstract][Full Text] [Related]
22. VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
Englisch A; Altvater B; Kailayangiri S; Hartmann W; Rossig C
Pediatr Blood Cancer; 2020 Oct; 67(10):e28313. PubMed ID: 32729251
[TBL] [Abstract][Full Text] [Related]
23. PD‑L1/PD‑1 axis serves an important role in natural killer cell‑induced cytotoxicity in osteosarcoma.
Zhang ML; Chen L; Li YJ; Kong DL
Oncol Rep; 2019 Nov; 42(5):2049-2056. PubMed ID: 31485666
[TBL] [Abstract][Full Text] [Related]
24. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells.
Ray AK; Somanchi SS; Dastgheyb N; Aquino-Lopez A; Cobanoglu ZE; Geier B; Lee DA
Pediatr Blood Cancer; 2019 Oct; 66(10):e27783. PubMed ID: 31304677
[TBL] [Abstract][Full Text] [Related]
25. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
26. Killing the killer: natural killer cells to treat Ewing's sarcoma.
Ahn YO; Weigel B; Verneris MR
Clin Cancer Res; 2010 Aug; 16(15):3819-21. PubMed ID: 20554750
[TBL] [Abstract][Full Text] [Related]
27. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation.
Henrich IC; Jain K; Young R; Quick L; Lindsay JM; Park DH; Oliveira AM; Blobel GA; Chou MM
Cancer Res; 2021 Apr; 81(8):2171-2183. PubMed ID: 33558334
[TBL] [Abstract][Full Text] [Related]
29. Overview of conference on sarcomas of soft tissue and bone in childhood.
Glicksman AS; Maurer HM; Vietti TJ
Med Pediatr Oncol; 1979; 7(1):55-67. PubMed ID: 293494
[No Abstract] [Full Text] [Related]
30. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.
Canter RJ; Grossenbacher SK; Foltz JA; Sturgill IR; Park JS; Luna JI; Kent MS; Culp WTN; Chen M; Modiano JF; Monjazeb AM; Lee DA; Murphy WJ
J Immunother Cancer; 2017 Dec; 5(1):98. PubMed ID: 29254507
[TBL] [Abstract][Full Text] [Related]
31. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.
Kaweme NM; Zhou F
Front Immunol; 2021; 12():683381. PubMed ID: 34220833
[TBL] [Abstract][Full Text] [Related]
32. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
33. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
Kailayangiri S; Altvater B; Meltzer J; Pscherer S; Luecke A; Dierkes C; Titze U; Leuchte K; Landmeier S; Hotfilder M; Dirksen U; Hardes J; Gosheger G; Juergens H; Rossig C
Br J Cancer; 2012 Mar; 106(6):1123-33. PubMed ID: 22374462
[TBL] [Abstract][Full Text] [Related]
34. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
35. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
36. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
[TBL] [Abstract][Full Text] [Related]
37. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Nishioka T; Fukunaga S; Futani H; Okamura H; Terada N
Oncol Rep; 2010 Dec; 24(6):1621-7. PubMed ID: 21042760
[TBL] [Abstract][Full Text] [Related]
38. An evolutionary framework for treating pediatric sarcomas.
Reed DR; Metts J; Pressley M; Fridley BL; Hayashi M; Isakoff MS; Loeb DM; Makanji R; Roberts RD; Trucco M; Wagner LM; Alexandrow MG; Gatenby RA; Brown JS
Cancer; 2020 Jun; 126(11):2577-2587. PubMed ID: 32176331
[TBL] [Abstract][Full Text] [Related]
39. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation.
Kuçi S; Rettinger E; Voss B; Weber G; Stais M; Kreyenberg H; Willasch A; Kuçi Z; Koscielniak E; Klöss S; von Laer D; Klingebiel T; Bader P
Haematologica; 2010 Sep; 95(9):1579-86. PubMed ID: 20378565
[TBL] [Abstract][Full Text] [Related]
40. ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C; Moser LM; Kreyenberg H; Bonig HB; Tonn T; Wels WS; Gradhand E; Ullrich E; Meister MT; Koerkamp MG; Holstege FCP; Drost J; Klusmann JH; Bader P; Merker M; Rettinger E
Front Immunol; 2023; 14():1228894. PubMed ID: 37662907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
